AC Immune SA (ACIU) has released an update.
AC Immune SA, a Swiss biopharmaceutical company, has forged a significant partnership with Takeda, receiving a $100 million upfront payment for their active immunotherapy ACI-24.060 targeting Alzheimer’s disease, with potential future payments up to approximately $2.1 billion. The company’s robust pipeline includes 16 programs with one in Phase 3 and five in Phase 2, leveraging proprietary technology platforms aimed at treating neurodegenerative diseases. AC Immune is well-funded into 2027, suggesting a strong financial position for continued development in precision medicine for targeted therapies.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
